Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498482 | 0.98 | PARP10 (0.53) | PARP10MAOBSMN1; SMN2GRM5TDP1 | |
| SCHEMBL14456120 | 0.98 | PARP10 (0.53) | PARP10MAOBSMN1; SMN2GRM5TDP1 | |
| SCHEMBL14456118 | 0.95 | PARP10 (0.55) | PARP10MAOBSMN1; SMN2GRM5TDP1 | |
| SCHEMBL6735884 | 0.90 | PARP10 (0.47) | PARP10MAOBSMN1; SMN2GRM5TDP1 | |
| SCHEMBL6734353 | 0.90 | PARP10 (0.47) | PARP10MAOBSMN1; SMN2GRM5TDP1 | |
| SCHEMBL6734481 | 0.90 | PARP10 (0.47) | PARP10MAOBSMN1; SMN2GRM5TDP1 | |
| SCHEMBL13498488 | 0.88 | PARP10 (0.46) | PARP10MAOBSMN1; SMN2GRM5TDP1 | |
| SCHEMBL13498487 | 0.88 | PARP10 (0.50) | PARP10MAOBSMN1; SMN2TDP1HDAC8 | |
| SCHEMBL8264804 | 0.87 | MAOB (0.53) | MAOBGRM5TACR1 | |
| SCHEMBL13888671 | 0.85 | PARP10 (0.44) | PARP10MAOBSMN1; SMN2HDAC8ALKBH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180074066-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| US-20180074067-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| US-20160349267-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2016-12-01 | — | — | US | disclosed |
| US-9139869-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140206557-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8362193-B2 | Reagents for directed biomarker signal amplification | SIRIGEN GROUP LIMITED (GB) | 2013-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180074066-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | PARP10 1144/4885MAOB 2992/4885SMN1; SMN2 3493/4885 |
| US-20160349267-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | PARP10 1144/4885MAOB 2992/4885SMN1; SMN2 3493/4885 |
| US-20180074067-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | PARP10 1144/4885MAOB 2992/4885SMN1; SMN2 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.